Analysis of major histocompatibility complex class I, tap expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease

Paul G. Murray, Christothea M. Constandinou, John Crocker, Lawrence S. Young, Richard F Ambinder

Research output: Contribution to journalArticle

Abstract

The Epstein-Barr virus (EBV)-encoded latent membrane proteins, LMP1 and LMP2, are consistently expressed by the malignant Hodgkin/Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD). Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, yet in HD the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 and LMP2 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen processing/presentation or in CTL function. This study has used immunohistochemistry to show high-level expression of major histocompatibility complex (MHC) class I molecules by the HRS cells of EBV- associated HD and either low level or absence of expression of MHC class I molecules on HRS cells of EBV-negative tumors. In addition, HRS cells expressed high levels of transporter-associated proteins (TAP-1, -2), irrespective of the presence of latent EBV infection. These results suggest that global downregulation of MHC class I molecules does not account for the apparent ability of EBV-infected HRS cells to evade CTL responses, but may be important in the understanding of EBV-negative disease. We have also sequenced an epitope in LMP2A (CLGGLLTMV) that is restricted through HLA A2.1, a relatively common allele in Caucasian populations, and showed that this epitope is wild type in a small group of EBV-associated HLA A2.1- positive HD tumors. This result may be relevant to proposed immunotherapeutic approaches for EBV-positive HD patients that target CTL epitopes.

Original languageEnglish (US)
Pages (from-to)2477-2483
Number of pages7
JournalBlood
Volume92
Issue number7
StatePublished - Oct 1 1998

Fingerprint

Major Histocompatibility Complex
Human Herpesvirus 4
Hodgkin Disease
Viruses
Epitopes
Reed-Sternberg Cells
T-cells
Cytotoxic T-Lymphocytes
Antigen Presentation
Molecules
Tumors
T-Lymphocyte Epitopes
Epstein-Barr Virus Infections
Virus Diseases
Membrane Proteins
Proteins
Blood
Cells
Neoplasms
Down-Regulation

ASJC Scopus subject areas

  • Hematology

Cite this

Analysis of major histocompatibility complex class I, tap expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. / Murray, Paul G.; Constandinou, Christothea M.; Crocker, John; Young, Lawrence S.; Ambinder, Richard F.

In: Blood, Vol. 92, No. 7, 01.10.1998, p. 2477-2483.

Research output: Contribution to journalArticle

Murray, Paul G. ; Constandinou, Christothea M. ; Crocker, John ; Young, Lawrence S. ; Ambinder, Richard F. / Analysis of major histocompatibility complex class I, tap expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. In: Blood. 1998 ; Vol. 92, No. 7. pp. 2477-2483.
@article{a78f7d9ef22745fb96daeca458375548,
title = "Analysis of major histocompatibility complex class I, tap expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease",
abstract = "The Epstein-Barr virus (EBV)-encoded latent membrane proteins, LMP1 and LMP2, are consistently expressed by the malignant Hodgkin/Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD). Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, yet in HD the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 and LMP2 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen processing/presentation or in CTL function. This study has used immunohistochemistry to show high-level expression of major histocompatibility complex (MHC) class I molecules by the HRS cells of EBV- associated HD and either low level or absence of expression of MHC class I molecules on HRS cells of EBV-negative tumors. In addition, HRS cells expressed high levels of transporter-associated proteins (TAP-1, -2), irrespective of the presence of latent EBV infection. These results suggest that global downregulation of MHC class I molecules does not account for the apparent ability of EBV-infected HRS cells to evade CTL responses, but may be important in the understanding of EBV-negative disease. We have also sequenced an epitope in LMP2A (CLGGLLTMV) that is restricted through HLA A2.1, a relatively common allele in Caucasian populations, and showed that this epitope is wild type in a small group of EBV-associated HLA A2.1- positive HD tumors. This result may be relevant to proposed immunotherapeutic approaches for EBV-positive HD patients that target CTL epitopes.",
author = "Murray, {Paul G.} and Constandinou, {Christothea M.} and John Crocker and Young, {Lawrence S.} and Ambinder, {Richard F}",
year = "1998",
month = "10",
day = "1",
language = "English (US)",
volume = "92",
pages = "2477--2483",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Analysis of major histocompatibility complex class I, tap expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease

AU - Murray, Paul G.

AU - Constandinou, Christothea M.

AU - Crocker, John

AU - Young, Lawrence S.

AU - Ambinder, Richard F

PY - 1998/10/1

Y1 - 1998/10/1

N2 - The Epstein-Barr virus (EBV)-encoded latent membrane proteins, LMP1 and LMP2, are consistently expressed by the malignant Hodgkin/Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD). Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, yet in HD the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 and LMP2 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen processing/presentation or in CTL function. This study has used immunohistochemistry to show high-level expression of major histocompatibility complex (MHC) class I molecules by the HRS cells of EBV- associated HD and either low level or absence of expression of MHC class I molecules on HRS cells of EBV-negative tumors. In addition, HRS cells expressed high levels of transporter-associated proteins (TAP-1, -2), irrespective of the presence of latent EBV infection. These results suggest that global downregulation of MHC class I molecules does not account for the apparent ability of EBV-infected HRS cells to evade CTL responses, but may be important in the understanding of EBV-negative disease. We have also sequenced an epitope in LMP2A (CLGGLLTMV) that is restricted through HLA A2.1, a relatively common allele in Caucasian populations, and showed that this epitope is wild type in a small group of EBV-associated HLA A2.1- positive HD tumors. This result may be relevant to proposed immunotherapeutic approaches for EBV-positive HD patients that target CTL epitopes.

AB - The Epstein-Barr virus (EBV)-encoded latent membrane proteins, LMP1 and LMP2, are consistently expressed by the malignant Hodgkin/Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD). Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, yet in HD the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 and LMP2 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen processing/presentation or in CTL function. This study has used immunohistochemistry to show high-level expression of major histocompatibility complex (MHC) class I molecules by the HRS cells of EBV- associated HD and either low level or absence of expression of MHC class I molecules on HRS cells of EBV-negative tumors. In addition, HRS cells expressed high levels of transporter-associated proteins (TAP-1, -2), irrespective of the presence of latent EBV infection. These results suggest that global downregulation of MHC class I molecules does not account for the apparent ability of EBV-infected HRS cells to evade CTL responses, but may be important in the understanding of EBV-negative disease. We have also sequenced an epitope in LMP2A (CLGGLLTMV) that is restricted through HLA A2.1, a relatively common allele in Caucasian populations, and showed that this epitope is wild type in a small group of EBV-associated HLA A2.1- positive HD tumors. This result may be relevant to proposed immunotherapeutic approaches for EBV-positive HD patients that target CTL epitopes.

UR - http://www.scopus.com/inward/record.url?scp=0032189834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032189834&partnerID=8YFLogxK

M3 - Article

C2 - 9746788

AN - SCOPUS:0032189834

VL - 92

SP - 2477

EP - 2483

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -